What is Zacks Research's Estimate for VRTX FY2027 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Investment analysts at Zacks Research increased their FY2027 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued on Wednesday, April 23rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings per share of $18.04 for the year, up from their previous forecast of $18.02. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Several other research analysts have also commented on the stock. Bank of America lifted their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a report on Monday, March 31st. Morgan Stanley increased their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and boosted their price objective for the company from $408.00 to $424.00 in a research report on Tuesday, February 11th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $514.91.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $493.84 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a fifty day moving average price of $489.78 and a two-hundred day moving average price of $466.28. The company has a market cap of $126.81 billion, a PE ratio of -224.47, a P/E/G ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently made changes to their positions in the company. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at about $30,000. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $31,000. Sugar Maple Asset Management LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth $35,000. Golden State Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth $37,000. Finally, SJS Investment Consulting Inc. increased its holdings in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after buying an additional 30 shares during the period. Institutional investors own 90.96% of the company's stock.

Insider Buying and Selling

In other news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 in the last three months. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.